Needham & Company Maintains Hold Rating on Theravance Biopharma (TBPH), Analyst Sees no Meaningful Catalysts in 2022, Awaits Pipeline Progression
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Hold rating on Theravance Biopharma (NASDAQ: TBPH), following the company's Q1 report ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
